基本信息
浏览量:47
职业迁徙
个人简介
Samuel Broder is an American oncologist and medical researcher. He was a co-developer of some of the first effective drugs for the treatment of AIDS and was Director of the National Cancer Institute (NCI) from 1989 to 1995.
During the first years of the AIDS epidemic, he co-developed zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), which were the first effective drugs licensed for the treatment of AIDS. In 1989, he was appointed by President Ronald Reagan to be Director of the NCI. In this position he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). After leaving the NCI, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics. He is now Chief Medical Officer of Celera.
He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel Award.
研究兴趣
论文共 248 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
A. Tutt,A. Wang,R. Springall,K. Lau,K. Ryder, L. Kam Morgan,S. Broder,L. Esserman,C. Gillett,J. Sninsky
Hongjin Huang,Mitchell L Shiffman,Ramsey C Cheung,Thomas J Layden,Scott Friedman,Olivia T Abar,Linda Yee,Anand P Chokkalingam,Steven J Schrodi,Jason Chan,Joseph J Catanese,Diane U Leong,David Ross,Xiaolan Hu,Alexander Monto,Linda B McAllister,Samuel Broder,Thomas White,John J Sninsky,Teresa L Wright
加载更多
作者统计
#Papers: 248
#Citation: 29932
H-Index: 82
G-Index: 173
Sociability: 7
Diversity: 0
Activity: 0
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn